Laurence Reid - 16 Mar 2023 Form 4 Insider Report for Decibel Therapeutics, Inc. (DBTX)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jeffrey Schulz, Attorney-in-Fact
Issuer symbol
DBTX
Transactions as of
16 Mar 2023
Transactions value $
$0
Form type
4
Filing time
17 Mar 2023, 16:24:32
Previous filing
28 Feb 2022
Next filing
25 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DBTX Common Stock Award $0 +195K +754.38% $0.00 221K 16 Mar 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DBTX Stock Options (right to buy) Award $0 +72K $0.00 72K 16 Mar 2023 Common Stock 72K $3.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of the Issuer's common stock issuable under 195,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025.
F2 Includes 195,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting.
F3 The option was granted on March 16, 2023. The shares underlying the option are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025.

Remarks:

President and Chief Executive Officer